Review article: Safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 6, 2016, Pages 674-696

  Banerjee, D ^a   Reddy, K R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ASUNAPREVIR; BECLABUVIR; BILIRUBIN; BOCEPREVIR; DACLATASVIR; DASABUVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ELBASVIR; GRAZOPREVIR; HEMOGLOBIN; INTERFERON; LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; OMBITASVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PARITAPREVIR; PEGINTERFERON; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNINDEXED DRUG; VELPATASVIR; ABT-450; ISOQUINOLINE DERIVATIVE; MACROCYCLIC COMPOUND; SULFONAMIDE;

ACUTE KIDNEY FAILURE; ANEMIA; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; COUGHING; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG FATALITY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HEMOPERITONEUM; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATOBILIARY DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; INSOMNIA; INTERSTITIAL PNEUMONIA; IRRITABILITY; KIDNEY FAILURE; LEUKOCYTE COUNT; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TOXICITY; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MONOTHERAPY; MULTIPLE ORGAN FAILURE; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY DISORDER; POPULATION RESEARCH; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SEIZURE; SEPSIS; SEPTIC SHOCK; THROMBOCYTE COUNT; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; AGED; COMBINATION DRUG THERAPY; FEMALE; HEPATITIS C, CHRONIC; MALE; MIDDLE AGED;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; ISOQUINOLINES; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; PROTEASE INHIBITORS; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; SULFONAMIDES;

EID: 84958595162     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13514     Document Type: Review

References (141)

1. Bukh J, Miller R, Purcell R,. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 41-63.
2. Lauer GM, Walker BD,. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
3. Martel-laferrie V, Bichoupan K, Dieterich DT,. Hepatitis C direct-acting antiviral agents changing the paradigm of hepatitis C treatment in HIV-infected patients. J Clin Gastroenterol 2014; 48: 106-12.
4. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
5. Fried MW, Buti M, Dore GJ, et al,. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-29.
6. Gane EJ, Stedman CA, Hyland RH, et al,. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44.
7. Chayama K, Takahashi S, Toyota J, et al,. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55: 742-8.
8. McHutchison JG, Lawitz EJ, Shiffman ML, et al,. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
9. Poynard T, Colombo M, Bruix J, et al,. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: 1618-28.e2.
10. Kwong AD, McNair L, Jacobson I, George S,. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Curr Opin Pharmacol 2008; 8: 522-31.
11. Gentile I, Buonomo AR, Zappulo E, et al,. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther Clin Risk Manag 2014; 10: 493-504.
12. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36 (5 Suppl 1): S3-20.
13. Fried MW,. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36 (5 Suppl. 1): S237-44.
14. Welsch C, Jesudian A, Zeuzem S, Jacobson I,. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012; 61 (Suppl. 1): i36-46.
15. Sherman KE, Flamm SL, Afdhal NH, et al,. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
16. Kwo PY, Lawitz EJ, McCone J, et al,. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet (London, England) 2010; 376: 705-16.
17. Lee LY, Tong CYW, Wong T, Wilkinson M,. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials. Int J Clin Pract 2012; 66: 342-55.
18. Elbaz T, El-Kassas M, Esmat G,. New era for management of chronic hepatitis C virus using direct antiviral agents: a review. J Adv Res 2015; 6: 301-10.
19. Shiffman ML,. Hepatitis C virus therapy in the direct acting antiviral era. Curr Opin Gastroenterol 2014; 30: 217-22.
20. Hayashi N, Izumi N, Kumada H, et al,. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014; 61: 219-27.
21. Izumi N, Hayashi N, Kumada H, et al,. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 2014; 49: 941-53.
22. Jacobson IM, Dore GJ, Foster GR, et al,. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-13.
23. Manns M, Marcellin P, Poordad F, et al,. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-26.
24. Forns X, Lawitz E, Zeuzem S, et al,. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146: 1669-79.e3.
25. Reddy KR, Zeuzem S, Zoulim F, et al,. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect Dis 2015; 15: 27-35.
26. Lawitz E, Mangia A, Wyles D, et al,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
27. Lawitz E, Sulkowski MS, Ghalib R, et al,. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-65.
28. Pungpapong S, Aqel B, Leise M, et al,. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015; 61: 1880-6.
29. Kwo P, Gitlin N, Nahass R, et al,. A phase 3, randomized, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and treatment-experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1 [abstract]. Presented at the 50th Annual Meeting of the European Association for the Study of Liver, Vienna; April 22-26, 2015. Abstract LP14.
30. Lawitz E, Matusow G, DeJesus E, et al,. A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2 [abstract]. Presented at the 50th Annual Meeting of the European Association for the Study of Liver, Vienna; April 22-26, 2015. Abstract LP04.
31. Andreone P, Colombo MG, Enejosa J V, et al,. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147 (2): 359-65.e1.
32. Hézode C, Asselah T, Reddy KR, et al,. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015; 385: 2502-9.
33. Klibanov OM, Gale SE, Santevecchi B,. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. Ann Pharmacother 2015; 49: 566-81.
34. Link JO, Taylor JG, Xu L, et al,. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem 2014; 57: 2033-46.
35. Charlton M, Everson GT, Flamm SL, et al,. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 3: 649-59.
36. Lawitz E, Poordad FF, Pang PS, et al,. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383: 515-23.
37. Zeuzem S, Berg T, Gane E, et al,. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146: 430-41.e6.
38. Hayashi N, Seto C, Kato M, Komada Y, Goto S,. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 2014; 49: 138-47.
39. Kumada H, Hayashi N, Izumi N, et al,. Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study. Hepatol Res 2015; 45: 501-13.
40. Scott J, Gilles L, Fu M, et al,. Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUEST-2 and PROMISE studies. J Viral Hepat 2014; 22: 639-50.
41. Sanford M,. Simeprevir: a review of its use in patients with chronic hepatitis C virus infection. Drugs 2015; 75: 183-96.
42. Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O,. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014; 20: 2902-12.
43. Strahotin CS, Babich M,. Hepatitis C variability, patterns of resistance, and impact on therapy. Adv Virol 2012; 2012: 267483.
44. Hulskotte EGJ, Feng H-P, Xuan F, et al,. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis 2013; 56: 718-26.
45. Crauwels HM, Kakuda TN,. Drug interactions with new and investigational antiretrovirals the authors' reply. Clin Pharmacokinet 2010; 49: 67-8.
46. Bunchorntavakul C, Reddy KR,. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2015; 42: 258-72.
47. Menon RM, Badri PS, Wang T, et al,. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol 2015; 63: 20-9.
48. Kiser JJ, Burton JR Jr, Everson GT,. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013; 10: 596-606.
49. Lindenbach BD, Rice CM,. Unravelling hepatitis C virus replication from genome to function. Nature 2005; 436: 933-8.
50. Li K, Foy E, Ferreon JC, et al,. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005; 8: 2992-7.
51. Perni RB, Almquist SJ, Byrn RA, et al,. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006; 50: 899-909.
52. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
53. European Association for Study of Liver. Guidelines EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199-236.
54. Shirota Y, Luo H, Qin W, et al,. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. J Biol Chem 2002; 277: 11149-55.
55. Roth D, Nelson D, Bruchfeld A, et al,. In treatment-naive and treatment-experienced patients with Hepatitis C genotype 1 infection and chronic kidney disease C-SURFER: study design C-SURFER: SVR12 Results. J Hepatol 2015; 62: S263-4.
56. Lawitz E, Gane E, Pearlman B, et al,. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet (London, England) 2015; 385: 1075-86.
57. Gane EJ, Hyland RH, Ying Y, et al., Safety and efficacy of short-duration treatment with GS-9857 combined with sofosbuvir/GS-5816 in treatment-naive and DAA-experienced genotype 1 patients with and without cirrhosis. J Hepatology 2014; 62: S264.
58. Beaulieu PL,. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Curr Opin Investig Drugs 2007; 8: 614-34.
59. Hong Z, Cameron CE, Walker MP, et al,. A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase. Virology 2001; 285: 6-11.
60. Wang M, Ng KK-S, Cherney MM, et al,. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J Biol Chem 2003; 278: 9489-95.
61. Koff RS,. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014; 39: 478-87.
62. Bunchorntavakul C, Reddy KR,. Ribavirin: how does it work and is it still needed? Curr Hepat Rep 2011; 10: 168-78.
63. Feld JJ, Hoofnagle JH,. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-72.
64. Feld JJ, Lutchman GA, Heller T, et al,. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010; 139: 154-62.e4.
65. Thomas E, Ghany MG, Liang TJ,. The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother 2013; 23: 1-12.
66. Poordad F, Lawitz E, Reddy KR, et al,. Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection-a randomized trial. Gastroenterology 2013; 145: 1035-44.e5.
67. Lau JYN, Tam RC, Liang TJ, Hong Z,. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 1002-9.
68. Krampera M, Cosmi L, Angeli R, et al,. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386-98.
69. Rosenquist Å, Samuelsson B, Johansson P-O, et al,. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. J Med Chem 2014; 57: 1673-93.
70. You DM, Pockros PJ,. Simeprevir for the treatment of chronic hepatitis C. Expert Opin Pharmacother 2013; 14: 2581-9.
71. Gaetano JN,. Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. Drug Healthc Patient Saf 2014; 6: 37-45.
72. OLYSIO (Simeprevir) Capsules: Pacakge Insert. Titusville: Jansen Pharmaceuticals, Inc, 2013. Available at: https://www.olysio.com/shared/product/olysio/prescribing-information.pdf. Published Nov 2013 (accessed 15 Nov 2015).
73. Janssen-Cilag. OLYSIO (simeprevir) capsules, for oral use: US prescribing information 2015: 1-48. Available at: http://www.olysio.com/shared/product/olysio/prescribing-information.pdf (accessed 15 Nov 2015).
74. Sane RS, Steinmann GG, Huang Q, et al,. Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients. J Pharmacol Exp Ther 2014; 351: 403-12.
75. Huisman MT, Snoeys J, Monbaliu J, et al,. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. Hepatology 2010; 52 (Suppl. 1): 461A-2A.
76. Storck H,. Photoallergy and photosensitivity due to systemically administered drugs. Arch Dermatol 1965; 91: 469-82.
77. United States of America. Food and Drug Administration. Center for Drug Evaluation and Research. Medical Review TMC 435. By Brenda Carr. SIlver Spring, MD: Department of Health and Human Services, 2013. Web. 10 Nov 2015.
78. Moore DE,. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 2002; 25: 345-72.
79. Interstate Shellfish Sanitation Conference. Appendix: WHO toxicity grading scale for determining the severity of adverse events 2003: 132-135. Available at: http://www.icssc.org/Documents/Resources/AEManual2003AppendicesFebruary-06-2003 final.pdf (accessed 9 Nov 2015).
80. Sekar V, Verloes R, Meyvisch P, et al,. Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers. J Hepatol 2010; 52: S416.
81. FDA. Presented at Antiviral Drugs Advisory Committee Meeting Briefing Document Treatment of Patients with Chronic Hepatitis C NDA 205123. 2013; (October): 1-121.
82. Ouwerkerk-Mahadevan S, Simion A, Spittaels K, Beumont-Mauviel M,. Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment. J Hepatol 2013; 58: S365.
83. Albarmawi A, Czock D, Gauss A, et al,. CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores. Br J Clin Pharmacol 2013; 77: 160-9.
84. Tateishi T,. CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. Clin Pharmacol Ther 2001; 69: 333-9.
85. Feld JJ, Kowdley KV, Coakley E, et al,. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-603.
86. Poordad F, Hezode C, Trinh R, et al,. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-82.
87. Ferenci P, Bernstein D, Lalezari J, et al,. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983-92.
88. Zeuzem S, Jacobson IM, Baykal T, et al,. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604-14.
89. Sulkowski MS, Eron JJ, Wyles D, et al,. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313: 1223-31.
90. Kwo PY, Mantry PS, Coakley E, et al,. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375-82.
91. Cada DJ, Leonard J, Levien TL, Baker DE,. Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir. Hosp Pharm 2015; 50: 396-412.
92. AbbVie Limited. Viekirax 12.5 mg/75 mg/50 mg film-coated tablets: EU summary of product characteristics, 2015. Available at: http://www.ema.europa.eu (accessed 9 Nov 2015).
93. AbbVie Limited. Exviera 250 mg film-coated tablets: EU summary of product characteristics, 2015. Available at: http://www.ema.europa.eu (accessed 9 Nov 2015).
94. Eley T, Garimella T, Li W, Bertz RJ,. Asunaprevir: a review of preclinical and clinical pharmacokinetics and drug-drug interactions. Clin Pharmacokinet 2015; 54: 1205-22. doi: 10.1007/s40262-015-0299-6
95. Kumada H, Suzuki Y, Ikeda K, et al,. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59: 2083-91.
96. Lok AS, Gardiner DF, Hézode C, et al,. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014; 60: 490-9.
97. Poordad F, Sievert W, Mollison L,. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 2014; 60: 1267A-8A.
98. Manns M, Pol S, Jacobson IM, et al,. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet (London, England) 2014; 384: 1597-605.
99. Eley T, Gardiner D, Persson A, et al,. Evaluation of drug interaction potential of the HCV protease inhibitor asunaprevir (ASV; BMS 650032) at 200 mg twice daily (bid) in metabolic cocktail and p-glycoprotein (P-gp) probe studies in healthy volunteers [abstract 381]. Hepatology 2011; 54 (Suppl.1): 548A.
100. Pol S, Ghalib RH, Rustgi VK, et al,. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012; 12: 671-7.
101. Muir AJ, Poordad F, Lalezari J,. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA 2014; 60: 1267A-8A.
102. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al,. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-21.
103. Nelson DR, Cooper JN, Lalezari JP, et al,. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61: 1127-35.
104. Daklinza. [Package Insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2015.
105. Afdhal N, Zeuzem S, Kwo P, et al,. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
106. Afdhal N, Reddy KR, Nelson DR, et al,. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93.
107. Kowdley KV, Gordon SC, Reddy KR, et al,. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88.
108. Alqahtani S a, Afdhal N, Zeuzem S, et al,. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials. Hepatology 2015; 62: 25-30.
109. Cornpropst M, Denning J, Clemons D, et al,. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. J Hepatol 2012; 56: S433.
110. Keating GM,. Sofosbuvir: a review of its use in patients with chronic hepatitis C. Drugs 2014; 74: 1127-46.
111. Jacobson IM, Gordon SC, Kowdley KV, et al,. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
112. Zeuzem S, Dusheiko GM, Salupere R, et al,. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001.
113. Naggie S, Cooper C, Saag M, et al,. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373: 705-13.
114. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J,. Pegylated interferon a-2a and -2b with ribavirin in treatment of chronic hepatitis C. Health Technol Assess 2004; 8: 1-125.
115. McHutchison JG, Gordon SC, Schiff ER, et al,. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Group. N Engl J Med 1998; 339: 1485-92.
116. Al Marzooqi SH, Feld JJ,. Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. Liver Int 2015; 35: 1923-33.
117. Saxena V, Nyberg L, Pauly M, et al,. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology 2015; 62: 715-25.
118. Jensen DM, O'Leary JG, Pockros PJ, et al,. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort [abstract]. Program and Abstracts of the 65th Annual Meeting of the American Association for the Study of Livers Diseases; 7-11 November 2014; Boston, MA. p. Abstract 45
119. Summa V, Ludmerer SW, McCauley JA, et al,. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012; 56: 4161-7.
120. Hézode C, Fontaine H, Dorival C, et al,. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013; 59: 434-41.
121. O'Brien AJ, Fullerton JN, Massey KA, et al,. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat Med 2014; 20: 518-23.
122. Manns M, Forns X, Samuel D, et al,. Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: preliminary results of the prospective SOLAR 2 trial. 2015 International Liver Congress: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, April 22-26, 2015. Abstract G02.
123. Flamm SL, Everson GT, Charlton M, et al,. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. 65th Annual Meeting of the American Association for the Study of LIver Diseases (AASLD). November 1-5, 2014; Boston, MA.
124. Poordad F, Schiff ERER, Vierling JMJ, et al,. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: phase 3 ALLY-1 study. J Hepatol 2015; 62: S261-2.
125. Charlton M, Gane E, Manns MP, et al,. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108-17.
126. Mogalian E, German P, Brainard D, et al,. Lack of a clinically significant pharmacokinetic drug-drug interaction between sofosbuvir and GS-5816 in healthy volunteers. Hepatology 2013; 58: 431A.
127. Gane EJ, Hyland RH, An D, et al,. Once-daily sofosbuvir with GS-5816 for 8 weeks with or without ribavirin in patients with HCV genotype 3 without cirrhosis results in high rates of SVR12: the ELECTRON-2 study. Hepatology 2014; 60 (4 suppl): 236A.
128. Dusheiko G, Manns M, Reddy K, et al,. Safety and tolerability of grazoprevir/elbasvir in patients with chronic hepatitis C: an integrated analysis of phase 2-3 trials. 2015 International Liver Congress: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, April 22-26, 2015. Abstract 712.
129. Tamaki K, Okubo A,. Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: first case report. World J Gastroenterol 2015; 21: 1009-13.
130. Syal G, Heldenbrand SD, Duarte-Rojo A,. Seizures as a potential complication of treatment with simeprevir and sofosbuvir. Am J Ther 2014; 2: 1-2.
131. Communications FDS. FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another DAA drug. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm439484.htm (accessed 1 Nov 2015)
132. Back DJ, Burger DM,. Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology 2015; 149: 1315-7.
133. Communications FDS. FDA Warns of Serious Liver Injury Risk With Hepatitis C Treatments Viekira Pak and Technivie. Silver Spring, MD, USA: Food and Drug Administration, 2015. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm468634.htm (accessed 1 Nov 2015).
134. Technivie [Package Insert]. North Chicago, IL: AbbVie Inc., 2015.
135. Brayer SW, Reddy KR,. Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy. Expert Rev Gastroenterol Hepatol 2015; 9: 547-58.
136. Ingiliz P, Christensen S, Mauss S, et al,. Sofosbuvir plus ledipasvir for 8 weeks in HCV mono- and HIV-HCV-coinfected patients: results from the German Hepatitis C Cohort (GECCO). 15th European AIDS Conference, October 21-24, 2015, Barcelona. Abstract PS7/5.
137. Höner Zu Siederdissen C, Maasoumy B, Deterding K, et al,. Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting. Liver Int 2015; 35: 1845-52.
138. Te HS, Randall G, Jensen DM,. Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterol Hepatol 2007; 3: 218-25.
139. Archer M, Steinvoort C, Oderda G,. UPDATE: New Hepatitis C Combination Agents (Haroni and Viekira Pak). Salt Lake City, Utah: University of Utah College of Pharmacy, 2015: 1-39. Available at: https://medicaid.utah.gov/pharmacy/ptcommittee/files/Criteria ReviewDocuments/2015.07HepatitisCCombinationAgents.pdf (accessed 3 Nov 2015).
140. Back D, Else I,. The importance of drug-drug interactions in the DAA era. Dig Liver Dis 2013; 45: S343-8.
141. Mitema D, Atta M,. The role of organic transporters in pharmacokinetics and nephrotoxicity of newer antiviral therapies for HIV and hepatitis C. Curr Drug Metab 2015; 16: 322-31.